PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2067384
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2067384
AI in Rare Disease Diagnostics market size was valued at US$ 1,708.9 Million in 2025, expanding at a CAGR of 29.0% from 2026 to 2033.
Artificial intelligence in rare disease diagnosis refers to a system that makes use of machine learning and pattern recognition to analyze complex clinical, genomic, and imaging data, where it can be used to potentially expedite recognition of disease biomarkers that would otherwise be missed. Artificial intelligence applications in the rare disease diagnostic market will experience growth due to the rising prevalence of newborn screenings across the globe, personalized medicine treatment options, and adoption of artificial intelligence and machine learning technologies in developing countries. In July 2025, PathAI launched its new product known as Precision Pathology Network (PPN). It is an AI-based platform aimed at extending the reach of pathology products based on artificial intelligence to promote initiatives on precision medicine. It assists in facilitating the personalization of treatment. As a result, more healthcare providers are using AI-powered diagnostics and precision medicine, which is expected to speed up the growth of AI in the rare disease diagnostics market.
AI in Rare Disease Diagnostics Market- Market Dynamics
Growing Need for Early and Accurate Rare Disease Diagnosis Driving Market Demand
Rising requirement for early & timely detection of rare diseases leads to rise in usage of new technology due to failure to detect earlier lead to wrong diagnosis of disease. Technological innovations such as genomic sequencing, and data processing via AI, help the physician diagnose rare diseases quickly & accurately. Early detection ensures proper intervention and effective treatment is given to patients.
There is increasing demand from the healthcare industry for AI-based diagnostic tools for early and accurate diagnosis of rare diseases, which would ensure that diagnosis of difficult diseases, mostly due to multiple genetic factors, happens quicker and with greater accuracy. For instance, in 2026, according to the World Economic Forum, more than 300 million people globally live with rare diseases, while the conditions encompass approximately 7,000 distinct disorders. Despite advances in genomics and precision medicine, many patients still face lengthy diagnostic delays and remain underserved due to fragmented healthcare data and limited disease awareness. However, despite the advancements in genomics and personalized medicine, patients still suffer from delayed diagnosis and under diagnosis because of lack of integration and insufficient disease awareness. Thus, in view of rising cases of rare diseases around the world, AI-powered diagnostics are gaining widespread adoption.
The Global AI in Rare Disease Diagnostics market is segmented on the basis of Component, Deployment Mode, Technology, Application, End User, and Region.
Machine learning under the technology segment holds a notable share in the AI in Rare Disease Diagnostics market because of the rising use by healthcare services, as well as by researchers, to analyze large volumes of data pertaining to clinical and genetic aspects for faster diagnosis. For instance, in May 2025, according to the OECD.org, adoption of machine learning has been growing rapidly in Germany, and based on the national survey carried out among companies in the country, 13.3% already use the technology of artificial intelligence, while 9.2% have plans to apply it in the future. In addition, another survey suggests that 23% of firms plan to use artificial intelligence. Thus, as the adoption rate increases among companies in healthcare, machine learning diagnostics for rare diseases can be expected to gain popularity.
The genetic disorders in application segment hold a prominent share in the AI in Rare Disease Diagnostics market because the use of artificial intelligence to analyze the genome and diagnose rare diseases has increased over time. For instance, according to Genetic Alliance Org UK, 80% of rare conditions are genetic in origin, and over 6,000 children in the UK are born each year with a genetic condition so rare that it remains undiagnosed or unnamed. Additionally, 1 in 4 patients with a rare condition wait at least three years to receive a confirmed diagnosis, underscoring the increasing healthcare challenges associated with the rising prevalence and complexity of genetic disorders. Hence, because rare disease cases are increasing, healthcare systems are relying on AI tools to diagnose patients faster and more easily.
AI in Rare Disease Diagnostics Market- Geographical Insights
Currently, North America holds a significant share of the AI in Rare Disease Diagnostics market because of the rising incidence rate of rare disease cases, increasing genomics studies, and supportive regulations. For instance, in Feb. 2026, according to the U.S. Food and Drug Administration (FDA) Gov., more than 10,000 rare diseases collectively affect over 30 million Americans, representing approximately 1 in every 10 people in the United States. Additionally, nearly 50% of individuals living with rare diseases are children, highlighting the growing healthcare burden and the increasing need for advanced diagnostic technologies and targeted treatment solutions for rare disease management. Therefore, North America is increasingly using AI to diagnose the growing number of rare disease cases.
The Asia-Pacific region is witnessing rapid growth in the AI in Rare Disease Diagnostics market because of developments in the healthcare sector, increased awareness regarding rare diseases, and growing use of AI solutions in diagnostics. For instance, in 2026, according to the Press Information Bureau (PIB), India is significantly strengthening its healthcare infrastructure through support from the PM-ABHIM (Pradhan Mantri-Ayushman Bharat Health Infrastructure Mission), as per PIB (Press Information Bureau). This includes development of 9,519 health and wellness centers, 5,456 urban health and wellness centers, 2,151 public health unit buildings, 744 integrated public health laboratories, and 622 critical care hospital building blocks. As a result, there will be an increase in rapid diagnosis of rare diseases using AI in the Asia-Pacific region.
Japan AI in Rare Disease Diagnostics Market- Country Insights
Japan is currently funding and supporting the development of technology within the field of health care, presenting great prospects for business operators involved in technological innovation. For instance, in 2026, according to the Commonwealth Fund, Japan's government remains a major healthcare financier, with public funding accounting for 87% of total health spending and older adults aged 65 years and above representing 29% of the population but accounting for 62% of healthcare expenditures. This highlights Japan's substantial government commitment toward supporting healthcare services for its aging population and maintaining universal healthcare access nationwide. Hence, Japan's older population and strong public healthcare system keep opening up new opportunities for healthcare innovation.
The major characteristic of the AI in the rare disease diagnostics market is the presence of leading firms like Bayer, BioMind, Congenica, Deep Genomics, and Enlitic. They are trying to create AI-based diagnostic tools using innovations and partnerships with others. They keep on investing in the development of analytics and machine learning technologies in this industry. In June 2025, BioMind launched the improved version of their BioMind AI diagnostic platform for analyzing rare neurological and imaging-based diseases. It uses deep learning and automated image analysis for analyzing the diseases. This initiative of BioMind has helped improve their standing in the field of artificial intelligence-assisted diagnostics. Hence, the constant improvement in the field of AI is positively impacting the accuracy of disease diagnosis in the market.
In January 2026, Enlitic expanded its Enlitic Curie(TM) Platform with advanced AI-powered medical imaging data standardization and diagnostic workflow capabilities, supporting healthcare providers in managing complex diagnostic datasets. Strengthens Enlitic's role in AI-enabled diagnostic infrastructure and improves data quality for rare disease detection and clinical decision-making.
In September 2025, Congenica was acquired by AI-driven genomic analysis company SeqOne to create a larger clinical genomics software platform focused on genomic interpretation and rare disease diagnostics. The combined organization serves more than 160 laboratories across 30 countries, strengthening capabilities in AI-powered genomic medicine. Enhances Congenica's global reach in rare disease diagnostics and strengthens its AI-based genomic analysis capabilities.